FDA Feedback on Axpaxli Puts Ocular Therapeutix in Focus

Positive FDA feedback on Axpaxli has put Ocular Therapeutix (OCUL) in the spotlight, as the company prepares a New Drug Application in wet age-related macular degeneration using data from its SOL-1 and SOL-R trials.

The recent FDA feedback appears to have supported positive momentum in Ocular Therapeutix’s 90 day share price return of 32.97%, even though the year to date share price return is down 16.75%. The 3 year total shareholder return of 90.70% highlights how sentiment has shifted over a longer period.

If Axpaxli’s progress has your attention, it could be a good moment to broaden your search across other healthcare opportunities and check out our 39 healthcare AI stocks.

With Ocular Therapeutix trading at $9.84 and sitting at a steep discount to some analyst targets and intrinsic estimates, the key question is whether investors are seeing a genuine mispricing here, or if the market is already factoring in Axpaxli’s potential growth.

Most Popular Narrative: 62.2% Undervalued

Against Ocular Therapeutix’s last close at $9.84, the most followed narrative points to a fair value of $26, which places a lot of weight on Axpaxli’s role in retinal disease.

The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6–12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease, unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.

Curious what kind of revenue curve and profit margin shift would need to sit behind that Axpaxli story, and what future earnings multiple ties it all together.

Result: Fair Value of $26 (UNDERVALUED)

However, this Axpaxli driven case for Ocular Therapeutix still rests on a single key asset, and any clinical or regulatory setback could quickly challenge the potential upside.

Another View on Ocular Therapeutix Valuation

The analyst narrative and fair value of $26 lean heavily on projected earnings and margins, but the market is also signaling something very different through the revenue multiple. Ocular Therapeutix currently trades on a P/S ratio of 41.4x, versus 5.8x for the US Pharmaceuticals industry, 10.6x for peers, and a fair ratio of just 0.1x. This suggests a lot of expectation is already priced in and raises the question of how much execution risk you are really comfortable with.

Next Steps

If the split between Axpaxli optimism and valuation caution feels finely balanced, move quickly to review the underlying data, stress test your own assumptions, and weigh the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Ocular Therapeutix?

If Ocular Therapeutix and Axpaxli have sharpened your focus, do not stop here. Broaden your watchlist now and give yourself more options before the market moves.

• Spot potential mispricing early by scanning companies that combine quality and attractive valuations through the 44 high quality undervalued stocks.
• Prioritise resilience by zeroing in on businesses with stronger financial footing using the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for under followed opportunities that may not be on everyone’s radar yet with the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.